XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.23.2

Note 5 - Transactions With Affiliated Companies | 6 Months Ended
--- | ---
Jun. 30, 2023
Notes to Financial Statements |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | Note 5. Transactions with affiliated companies A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities. Transactions related to investments in non-controlled affiliated companies for the three months ended June 30, 2023 were as follows:
|  |  |  |  |  |  |  |  |  | Three months ended June 30, 2023 |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |
Portfolio |  | March 31, |  |  |  |  |  |  |  |  |  |  | in/(out) at |  |  | Dividends |  |  | unrealized |  |  | Net realized |  |  | June 30, |
Company |  | 2023 |  |  | Purchases |  |  | Sales |  |  | fair value |  |  | declared |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2023 |
|  | (In thousands) |
Cadrenal Therapeutics, Inc. |  |  | 846 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 60 |  |  |  | — |  |  |  | 906 |
Total non-controlled affiliates |  | $ | 846 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 60 |  |  | $ | — |  |  | $ | 906 |
Transactions related to investments in non-controlled affiliated companies for the six months ended June 30, 2023 were as follows:
|  |  |  |  |  |  |  |  |  | Six months ended June 30, 2023 |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | June 30, |
Company |  | 2022 |  |  | Purchases |  |  | Payments |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2023 |
|  | (In thousands) |
Cadrenal Therapeutics, Inc. |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 906 |  |  | $ | — |  |  | $ | 906 |
Total non-controlled affiliates |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 906 |  |  | $ | — |  |  | $ | 906 |
For the three and six months ended June 30, 2022, there were no transactions related to investments in non-controlled affiliated companies. A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). For the three and six months ended June 30, 2023, there were no transactions related to investments in controlled affiliated companies. Transactions related to investments in controlled affiliated companies for the three months ended June 30, 2022 were as follows:
|  |  |  |  |  |  |  |  |  | Three months ended June 30, 2022 |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |
Portfolio |  | March 31, |  |  |  |  |  |  |  |  |  |  | in/(out) at |  |  | Dividends |  |  | unrealized |  |  | Net realized |  |  | June 30, |
Company |  | 2022 |  |  | Purchases |  |  | Sales |  |  | fair value |  |  | declared |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2022 |
|  | (In thousands) |
HESP LLC |  |  | — |  |  |  | — |  |  |  | (200 | ) |  |  | — |  |  |  | — |  |  |  | 1,400 |  |  |  | (1,200 | ) |  |  | — |
Total controlled affiliates |  | $ | — |  |  | $ | — |  |  | $ | (200 | ) |  | $ | — |  |  | $ | — |  |  | $ | 1,400 |  |  | $ | (1,200 | ) |  | $ | — |
Transactions related to investments in controlled affiliated companies for the six months ended June 30, 2022 were as follows:
|  |  |  |  |  |  |  |  |  | Six months ended June 30, 2022 |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | June 30, |
Company |  | 2021 |  |  | Purchases |  |  | Payments |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2022 |
|  | (In thousands) |
HESP LLC |  |  | — |  |  |  | — |  |  |  | (250 | ) |  |  | — |  |  |  | — |  |  |  | 1,450 |  |  |  | (1,200 | ) |  |  | — |
Total controlled affiliates |  | $ | — |  |  | $ | — |  |  | $ | (250 | ) |  | $ | — |  |  | $ | — |  |  | $ | 1,450 |  |  | $ | (1,200 | ) |  | $ | — |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//946-320/tableOfContent + Details
Name: | us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration